IL158342A0 - Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides - Google Patents

Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides

Info

Publication number
IL158342A0
IL158342A0 IL15834202A IL15834202A IL158342A0 IL 158342 A0 IL158342 A0 IL 158342A0 IL 15834202 A IL15834202 A IL 15834202A IL 15834202 A IL15834202 A IL 15834202A IL 158342 A0 IL158342 A0 IL 158342A0
Authority
IL
Israel
Prior art keywords
hla
prolamine
restricted
binding
methods
Prior art date
Application number
IL15834202A
Other languages
English (en)
Original Assignee
Academisch Ziekenhuis Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academisch Ziekenhuis Leiden filed Critical Academisch Ziekenhuis Leiden
Publication of IL158342A0 publication Critical patent/IL158342A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL15834202A 2001-04-12 2002-04-11 Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides IL158342A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01201377 2001-04-12
EP01204383 2001-11-16
PCT/NL2002/000235 WO2002083722A2 (en) 2001-04-12 2002-04-11 Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides

Publications (1)

Publication Number Publication Date
IL158342A0 true IL158342A0 (en) 2004-05-12

Family

ID=26076879

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15834202A IL158342A0 (en) 2001-04-12 2002-04-11 Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides

Country Status (7)

Country Link
US (1) US20040241161A1 (de)
EP (1) EP1377604B1 (de)
CA (1) CA2443886A1 (de)
IL (1) IL158342A0 (de)
MX (1) MXPA03009313A (de)
NO (1) NO20034588L (de)
WO (1) WO2002083722A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923306D0 (en) 1999-10-01 1999-12-08 Isis Innovation Diagnostic and therapeutic epitope, and transgenic plant
DE60336754D1 (de) * 2002-02-14 2011-05-26 Univ R Enzymbehandlung von nahrungsmitteln für zöliakie-sprue
US8143210B2 (en) 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
GB0212885D0 (en) 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
ES2383595T3 (es) 2002-11-20 2012-06-22 The Board Of Trustees Of The Leland Stanford Junior University Procedimiento de diagnóstico de la celiaquía
BRPI0510274B8 (pt) 2004-04-28 2021-05-25 Btg Int Ltd uso de um agente para tratar ou prevenir doença celíaca, composição farmacêutica compreendendo dito agente, método de diagnóstico de doença celíaca, ou suscetibilidade à doença celíaca, uso do dito agente para a preparação de um meio de diagnóstico e kit para realizar o dito método de diagnóstico
AU2011247868B2 (en) * 2004-04-28 2014-05-22 Btg International Limited Epitopes related to coeliac disease
US10105437B2 (en) 2004-04-28 2018-10-23 Btg International Limited Epitopes related to coeliac disease
EP1612558A1 (de) * 2004-06-30 2006-01-04 Academisch Ziekenhuis Leiden Verfahren zum Nachweis von Gluten
US8092794B2 (en) * 2006-03-15 2012-01-10 Isocell Pharma S.A. Pharmaceutical compositions comprising SODs and prolamine based peptide fragments
WO2008090126A1 (de) * 2007-01-22 2008-07-31 N-Zyme Biotec Gmbh Getränke für zöliakiepatienten und gluten/gliadin-sensitive personen und verfahren zur herstellung
US20090311727A1 (en) * 2008-04-21 2009-12-17 Bio-Rad Laboratories, Inc. Recombinant deamidated gliadin antigen
EP3269379A1 (de) 2008-11-30 2018-01-17 Immusant, Inc. Zusammensetzungen und verfahren zur behandlung von zöliakie
FR2942409B1 (fr) * 2009-02-20 2013-07-26 Natacha Voillot Composition pharmaceutique pour la prevention des avortements a repetition.
US20140037661A1 (en) * 2011-02-08 2014-02-06 Phadia Ab Wheat Antigens and Peptides for Diagnosis of Wheat Induced Hypersensitivity
EP3171171B1 (de) 2011-12-05 2018-07-18 Bio-rad Laboratories, Inc. Rekombinantes desamidiertes gliadin-antigen
US10449228B2 (en) 2013-09-10 2019-10-22 Immusant, Inc. Dosage of a gluten peptide composition
CA2962933A1 (en) 2014-09-29 2016-04-07 Immusant, Inc. Use of hla genetic status to assess or select treatment of celiac disease
US20200040085A1 (en) * 2017-02-27 2020-02-06 Chugai Seiyaku Kabushiki Kaisha Anti-hla-dq2.5/8 antibody and its use for the treatment of celiac disease
CR20230166A (es) 2020-09-18 2023-05-31 Chugai Pharmaceutical Co Ltd Anticuerpo anti antígenos de leucocitos humanos (hla) isoforma dq 2.5 y su uso para el tratamiento de la enfermedad celíaca

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0905518A1 (de) * 1997-09-23 1999-03-31 Academisch Ziekenhuis Leiden Peptiden spezifisch für Glutenempfindliche T-Zellen und Verwendung davon
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement

Also Published As

Publication number Publication date
WO2002083722A2 (en) 2002-10-24
CA2443886A1 (en) 2002-10-24
WO2002083722A3 (en) 2003-02-06
MXPA03009313A (es) 2004-11-12
NO20034588D0 (no) 2003-10-13
EP1377604A2 (de) 2004-01-07
NO20034588L (no) 2003-12-10
EP1377604B1 (de) 2014-12-31
US20040241161A1 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
IL158342A0 (en) Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides
EP1423120A4 (de) 2h-phthalazin-1-one und verfahren zu ihrer verwendung
IL160001A0 (en) Peptide based multimeric targeted contrast agents and methods for the preparation thereof
AU2002254224A1 (en) Apparatus and methods for capture of medical agents
EP1416884A4 (de) Abgabe von mitteln mit therapeutischen eigenschaften
HUP0303976A3 (en) Combination therapy using anti-egfr antibodies and hormone antagonists
AU5716901A (en) G protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same
AU8079901A (en) Promyostatin peptides and methods of using same
EP1379265A4 (de) Kurze bioaktive peptide und verfahren zu ihrer verwendung
HUP0401863A3 (en) Amino acid-copolymers for suppression of autoimmune diseases, and methods of use
AU2002362586A1 (en) Receptors and membrane-associated proteins
AU2002364699A8 (en) Receptors and membrane-associated proteins
IL156992A0 (en) Novel receptors for helicobacter pylori and use thereof
CA98995S (en) Base portion of an air-purifying device
GB0325624D0 (en) Use of microparticles for antigen delivery
AU2003222225A8 (en) Receptors and membrane-associated proteins
AU2002309970A1 (en) Receptors and membrane-associated proteins
AU2002253716A1 (en) Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides
AU2002360790A8 (en) Compositions and methods for the therapeutic use of an atonal-associated sequence for a gastrointestinal condition
AU2001271281A1 (en) Novel compositions for the expression of the human peptide histidine transporter1 and methods of use thereof
AU2003272799A8 (en) Receptors and membrane-associated proteins
AU2003295437A8 (en) Receptors and membrane-associated proteins
AU2002339850A8 (en) Excitatory glycine receptors and methods
AU2003262895A8 (en) Carboxypeptidase b related polypeptides and methods of use
IL166102A0 (en) Beta-sheet breaking peptides and their use